Pharmaceuticals News

Investigational WJ-MSC therapy associated with no deaths at 12 months and statistically significant improvements in long-term cognitive and motor outcomes Results support planned expansion of the...

Phase 1 Study Designed to Evaluate the Safety, Tolerability and Pharmacokinetics of AT-587 in Healthy Volunteers AT-587 is a Potential First-in Class Treatment for Hepatitis E Virus, a Serious Liver...

HAIFA, Israel, July 14, 2026 (GLOBE NEWSWIRE) -- Pluri Inc. (Nasdaq, TASE: PLUR), a biotechnology company leveraging a proprietary cell-based platform across multiple commercial verticals, today...

MÜV Bradfordville is located in the Tallahassee area on a commercial stretch of Thomasville Road that has an average daily traffic count of 13,305 vehicles1MÜV Bradfordville is the Company’s second...

Ramat Gan, Israel, July 14, 2026 (GLOBE NEWSWIRE) -- Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a clinical-stage biotechnology company developing a pipeline of proprietary small...

Financing supports Phase 2 development of SP001, Spero’s first immunology drug candidate, in-licensed from Innovent Biologics Transaction unlocks immediate value from future Utebzi (tebipenem pivoxil)...

Avere Therapeutics’ lead program, AVR-001, is a differentiated oral peptide interleukin-23 (IL-23) receptor antagonist, with Phase 1b psoriasis data supporting its potential to be rapidly developed as...

Under the terms of the agreement, Spero will receive exclusive global rights, excluding Greater China, to develop, research, manufacture, and commercialize SP001 (IBI355) Innovent will receive an...

From 647 nominations globally, Hummingbird Bioscience emerged as a winner, recognizing the company’s AI-first approach to drug discovery and development.

Company announcement no. 25 - 2614 July 2026 Transactions in connection with share buy-back program On 4 March 2026 NTG Nordic Transport Group (“NTG”) announced a share buy-back program, as...